Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors

Dr. Reddy’s fiscal Q2 2027 revenue fell 1.5% year over year to $905 million, as lower Lenalidomide sales were partly offset by demand in India and emerging markets; gross margin was 52.1%. Management said the underlying base business grew at a double-digit rate, Semaglutide supply is expected to be reloaded across Canada, Latin America and Africa by November 2026, and CDMO trailing-12-month revenue reached $100 million. Abatacept is targeting a U.S. FDA decision in December 2026, while the company continues investing in complex generics and other growth areas.

Analysis

The key issue is earnings quality, not the headline growth claim: excluding North American Lenalidomide makes the underlying business look healthier, but does not establish that replacement products can offset continued erosion in this concentrated revenue stream. The 52.1% gross margin is a useful buffer, though mix and pricing—not demand alone—will determine whether that resilience persists.

Semaglutide supply restoration is a near-term execution test, not yet a durable growth catalyst. Shipments to a partner do not prove downstream availability, sell-through, or repeatable API yields. If restocking succeeds, it may support revenue across several markets; if supply resumes only briefly, investors could discount management’s scale-up resolution. Broader generic GLP-1 competition and regulatory constraints also limit the inference that restored supply translates into attractive economics.

The December 2026 Abatacept decision is a binary catalyst, but approval would still leave commercialization, interchangeability, access, and uptake to prove. CDMO growth can diversify revenue, yet trailing revenue alone says little about margins, capacity utilization, or customer concentration. The contrarian risk is that investors reward pipeline optionality while underweighting ongoing Lenalidomide erosion and the gap between regulatory progress and commercial contribution. Near term, the evidence is insufficient to support an outright directional position without valuation, consensus, and product-level sales data.

Key Decisions for Investors

• No immediate outright RDY trade on this call alone. Before taking a position, verify North American Lenalidomide sales trajectory, the size of its contribution to consolidated revenue, and whether base-business growth is translating into operating profit and cash flow.
• Treat Semaglutide as a November execution watch: seek evidence of market restocking and subsequent sell-through, not just partner shipments. Failure to restore availability, or another API scale-up interruption, would weaken the near-term thesis.
• Track the December 2026 Abatacept FDA decision as an event catalyst. Consider defined-risk exposure only after confirming the application’s regulatory status and assessing commercial readiness; approval without credible access and launch plans may produce limited durable value.
• Reassess a cautious-to-constructive RDY view if core-market growth and margins hold while Lenalidomide declines moderate. Falsifiers include further consolidated revenue deterioration, margin slippage, delayed Semaglutide replenishment, or an adverse Abatacept regulatory outcome.